- Aug 2022
-
www.nature.com www.nature.com
-
Lucas, C., Vogels, C. B. F., Yildirim, I., Rothman, J. E., Lu, P., Monteiro, V., Gelhausen, J. R., Campbell, M., Silva, J., Tabachikova, A., Peña-Hernandez, M. A., Muenker, M. C., Breban, M. I., Fauver, J. R., Mohanty, S., Huang, J., Shaw, A. C., Ko, A. I., Omer, S. B., … Iwasaki, A. (2021). Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04085-y
-
-
twitter.com twitter.com
-
Sandra Ciesek. (2021, December 8). Unsere ersten Daten zur Neutralisation von Omicron versus Delta sind fertig: 2x Biontech, 2x Moderna, 1xAZ/1x Biontech nach 6 Monaten 0% Neutralisation bei Omicron, auch 3x Biontech 3 Monate nach Booster nur 25% NT versus 95% bei Delta. Bis zu 37fache Reduktion Delta vs. Omicron https://t.co/w0gHww26sg [Tweet]. @CiesekSandra. https://twitter.com/CiesekSandra/status/1468465347519041539
-
-
www.nature.com www.nature.com
-
Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., Zepeda, S. K., Papa, G., Kemp, S. A., Ikeda, T., Toyoda, M., Tan, T. S., Kuramochi, J., Mitsunaga, S., Ueno, T., … Gupta, R. K. (2022). Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature, 1–1. https://doi.org/10.1038/s41586-022-04474-x
-
-
twitter.com twitter.com
-
Yaniv Erlich. (2021, December 8). Updated table of Omicron neuts studies with @Pfizer results (which did the worst job in terms of reporting raw data). Strong discrepancy between studies with live vs pseudo. Https://t.co/InQuWMAm4l [Tweet]. @erlichya. https://twitter.com/erlichya/status/1468580675007795204
-
-
twitter.com twitter.com
-
ReconfigBehSci. (2021, December 12). RT @EricTopol: If you think Prior Covid protects against Omicron (B.1.1.529), think again https://medrxiv.org/content/10.1101/2021.12.08.21267491v1 and "Neutralizing antibo… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1470434736304803845
-
-
twitter.com twitter.com
-
Eric Topol. (2021, October 27). 'The benefit of a third [booster] dose in reducing transmission is sizeable and increases with vaccine coverage and contact rates among individuals." https://medrxiv.org/content/10.1101/2021.10.25.21265500v1 by @billygardner and @DiseaseEcology https://t.co/zAZcJgF1nJ [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1453153076165021696
-
- Apr 2022
-
twitter.com twitter.com
-
Alex Sigal [@sigallab]. (2021, December 7). We have completed our first experiments on neutralization of Omicron by Pfizer BNT162b2 vaccination elicited immunity Manuscript available at https://sigallab.net and should be available on medRxiv in the coming days [Tweet]. Twitter. https://twitter.com/sigallab/status/1468325159501287434
-
- Mar 2022
-
twitter.com twitter.com
-
Trevor Bedford on Twitter. (n.d.). Twitter. Retrieved 29 March 2022, from https://twitter.com/trvrb/status/1466076761427304453
-
- Feb 2022
-
www.biorxiv.org www.biorxiv.org
-
Yamasoba, D., Kimura, I., Nasser, H., Morioka, Y., Nao, N., Ito, J., Uriu, K., Tsuda, M., Zahradnik, J., Shirakawa, K., Suzuki, R., Kishimoto, M., Kosugi, Y., Kobiyama, K., Hara, T., Toyoda, M., Tanaka, Y. L., Butlertanaka, E. P., Shimizu, R., … Sato, K. (2022). Virological characteristics of SARS-CoV-2 BA.2 variant (p. 2022.02.14.480335). bioRxiv. https://doi.org/10.1101/2022.02.14.480335
-
-
www.sciencedirect.com www.sciencedirect.com
-
Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S. Y., Boutin, M., Bourassa, C., Beaudoin-Bussières, G., Bo, Y., Ding, S., Laumaea, A., Vézina, D., Perreault, J., Gokool, L., Morrisseau, C., Arlotto, P., Fournier, É., Guilbault, A., Delisle, B., Levade, I., … Finzi, A. (2022). SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses. Cell Reports, 0(0). https://doi.org/10.1016/j.celrep.2022.110429
-
- Jan 2022
-
www.medrxiv.org www.medrxiv.org
-
Gentles, L. E., Kehoe, L., Crawford, K. H. D., Lacombe, K., Dickerson, J., Wolf, C., Yuan, J., Schuler, S., Watson, J. T., Nyanseor, S., Briggs-Hagen, M., Saydah, S., Midgley, C. M., Pringle, K., Chu, H., Bloom, J. D., & Englund, J. A. (2022). Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time (p. 2022.01.14.22269235). medRxiv. https://doi.org/10.1101/2022.01.14.22269235
-
-
www.nejm.org www.nejm.org
-
Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., Tang, H., Manning, K. E., Edara, V.-V., Lai, L., Ellis, M., Moore, K. M., Floyd, K., Foster, S. L., Posavad, C. M., … Montefiori, D. C. (2022). SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMc2119912
-
- Dec 2021
-
www.medrxiv.org www.medrxiv.org
-
Wilhelm, A., Widera, M., Grikscheit, K., Toptan, T., Schenk, B., Pallas, C., Metzler, M., Kohmer, N., Hoehl, S., Helfritz, F. A., Wolf, T., Goetsch, U., & Ciesek, S. (2021). Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies (p. 2021.12.07.21267432). https://doi.org/10.1101/2021.12.07.21267432
-
-
www.medrxiv.org www.medrxiv.org11779531
-
Garcia-Beltran, W. F., Denis, K. J. S., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., Feldman, J., Gregory, D. J., Poznansky, M. C., Schmidt, A. G., Iafrate, A. J., Naranbhai, V., & Balazs, A. B. (2021). MRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (p. 2021.12.14.21267755). https://doi.org/10.1101/2021.12.14.21267755
-
- Jun 2021
-
poseidon01.ssrn.com poseidon01.ssrn.com
-
Parry, H. M., Tut, G., Faustini, S., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K., Amirthalingam, G., Charlton, S., Leung, S., Chiplin, E., Coombes, N. S., Bewley, K. R., Penn, E. J., Rowe, C., Otter, A., Watts, R., D’Arcangelo, S., … Moss, P. (2021). BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3816840
-
- Feb 2021
-
papers.ssrn.com papers.ssrn.com
-
Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W. M., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Saunders, K. O., Gnanakaran, S., Hengartner, N. W., Pajon, R., Smith, G., Dubovsky, F., Glenn, G. M., Korber, B. T., & Montefiori, D. C. (2021). SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines (SSRN Scholarly Paper ID 3777473). Social Science Research Network. https://papers.ssrn.com/abstract=3777473
-
- Sep 2020
-
pittsburgh.cbslocal.com pittsburgh.cbslocal.com
-
University Of Pittsburgh Scientists Discover Biomolecule That May Neutralize Coronavirus. (2020, September 15). https://pittsburgh.cbslocal.com/2020/09/15/coronavirus-university-pittsburgh-biomolecule-neutralize/
-
-
www.medrxiv.org www.medrxiv.org
-
Aziz, N. A., Corman, V. M., Echterhoff, A. K. C., Richter, A., Schmandke, A., Schmidt, M. L., Schmidt, T. H., Vries, F. M. D., Drosten, C., & Breteler, M. M. B. (2020). Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany. MedRxiv, 2020.08.24.20181206. https://doi.org/10.1101/2020.08.24.20181206
-
- Aug 2020
-
pubs.acs.org pubs.acs.org
-
Zhang, Q., Honko, A., Zhou, J., Gong, H., Downs, S. N., Vasquez, J. H., Fang, R. H., Gao, W., Griffiths, A., & Zhang, L. (2020). Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity. Nano Letters. https://doi.org/10.1021/acs.nanolett.0c02278
-
-
-
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., Navarro, M. J., Miranda, M. C., Pettie, D., Ravichandran, R., Kraft, J. C., Ogohara, C., Palser, A., Chalk, S., Lee, E.-C., … King, N. P. (2020). Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. BioRxiv, 2020.08.11.247395. https://doi.org/10.1101/2020.08.11.247395
-
-
www.medrxiv.org www.medrxiv.org
-
Rodda, L. B., Netland, J., Shehata, L., Pruner, K. B., Morawski, P. M., Thouvenel, C., Takehara, K. K., Eggenberger, J., Hemann, E. A., Waterman, H. R., Fahning, M. L., Chen, Y., Rathe, J., Stokes, C., Wrenn, S., Fiala, B., Carter, L. P., Hamerman, J. A., King, N. P., … Pepper, M. (2020). Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. MedRxiv, 2020.08.11.20171843. https://doi.org/10.1101/2020.08.11.20171843
-
-
-
Kreye, J., Reincke, S. M., Kornau, H.-C., Sánchez-Sendin, E., Corman, V. M., Liu, H., Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., Trimpert, J., Höltje, M., Dietert, K., Stöffler, L., Wardenburg, N. von, Hoof, S. van, Homeyer, M. A., Hoffmann, J., Abdelgawad, A., … Prüss, H. (2020). A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model. BioRxiv, 2020.08.15.252320. https://doi.org/10.1101/2020.08.15.252320
-
-
www.biorxiv.org www.biorxiv.org
-
Glasgow, A., Glasgow, J., Limonta, D., Solomon, P., Lui, I., Zhang, Y., Nix, M. A., Rettko, N. J., Lim, S. A., Zha, S., Yamin, R., Kao, K., Rosenberg, O. S., Ravetch, J. V., Wiita, A. P., Leung, K. K., Zhou, X. X., Hobman, T. C., Kortemme, T., & Wells, J. A. (2020). Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. BioRxiv, 2020.07.31.231746. https://doi.org/10.1101/2020.07.31.231746
-
- May 2020
-
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
-
Wang, C., Li, W., Drabek, D. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 11, 2251 (2020). https://doi.org/10.1038/s41467-020-16256-y
-